Acorda Therapeutics Announces Departure of Chief, Organization Operations

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that David Lawrence, Main, Small business Operations and its principal accounting and economic officer, is resigning from the Business successful mid-March, 2021. Mr. Lawrence will acquire a leadership posture at an early-phase biotechnology corporation.

“Dave has been an significant aspect of Acorda’s management team above the earlier 22 several years and we are grateful for the a lot of contributions he has built to the Enterprise,” stated Ron Cohen, Acorda’s President and CEO. “While we will overlook him, we guidance his fascination in discovering a new period of his job, and would like him perfectly in his subsequent chance.”

“I am very pleased to have been section of aiding Acorda develop from a smaller, non-public corporation to a general public, commercial firm that has introduced crucial new therapies to folks residing with neurological conditions, including Parkinson’s and several sclerosis,” mentioned Mr. Lawrence. “Pursuing our just lately introduced advancements to Acorda’s monetary composition, I am leaving the firm in an exceptional place, and will be cheering it on to ongoing achievements.”

Robert Morales, Acorda’s Vice President of Finance and Controller, will think the roles of interim principal accounting officer and interim principal financial officer.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of men and women with neurological ailments. INBRIJA is accredited for intermittent treatment of OFF episodes in adults with Parkinson’s disorder taken care of with carbidopa/levodopa. INBRIJA is not to be utilised by individuals who consider or have taken a nonselective monoamine oxidase inhibitor these types of as phenelzine or tranylcypromine inside the previous two months. INBRIJA makes use of Acorda’s impressive ARCUS® pulmonary shipping technique, a know-how system intended to provide medication by inhalation. Acorda also marketplaces the branded AMPYRA® (dalfampridine) Extended Launch Tablets, 10 mg.

Ahead-Seeking Statements

This push launch includes forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, aims, ideas or potential clients ought to be thought of forward-hunting. These statements are issue to risks and uncertainties that could lead to genuine results to differ materially, together with: we may not be equipped to properly sector AMPYRA, INBRIJA or any other products under development the COVID-19 pandemic, like connected quarantines and travel limitations, and the possible for the illness to have an affect on our workers or consultants or all those that function for other providers we depend upon, could have a content adverse effect on our organization operations or products product sales our skill to elevate extra money to finance our functions, repay fantastic indebtedness or fulfill other obligations, and our potential to command our fees or lower prepared expenditures and acquire other actions which are essential for us to continue on as a likely issue dangers associated with the trading of our prevalent inventory and our reverse stock split risks relevant to our workforce, including our ability to notice the expected rewards of our corporate restructuring hazards connected with advanced, regulated producing procedures for prescribed drugs, which could have an impact on whether or not we have ample commercial provide of INBRIJA to satisfy industry demand from customers our reliance on 3rd-occasion suppliers for the generation of business supplies of AMPYRA and INBRIJA 3rd occasion payers (including governmental agencies) may perhaps not reimburse for the use of INBRIJA or our other solutions at satisfactory fees or at all and may possibly impose restrictive prior authorization needs that limit or block prescriptions competitors for INBRIJA, AMPYRA and other goods we may well create and market in the foreseeable future, which include increasing level of competition and accompanying decline of revenues in the U.S. from generic variations of AMPYRA (dalfampridine) next our reduction of patent exclusivity the capability to recognize the advantages predicted from acquisitions, among the other good reasons simply because obtained progress plans are typically topic to all the risks inherent in the drug improvement process and our knowledge of the pitfalls precisely pertinent to obtained applications usually improves around time the possibility of unfavorable benefits from foreseeable future experiments of INBRIJA (levodopa inhalation powder) or from our other investigation and enhancement systems, or any other obtained or in-licensed plans the occurrence of adverse basic safety occasions with our goods the final result (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, which include, without limitation, collective, representative or class action litigation failure to shield our mental residence, to defend against the intellectual assets statements of other people or to get third get together intellectual house licenses needed for the commercialization of our merchandise and failure to comply with regulatory needs could end result in adverse motion by regulatory agencies.

These and other challenges are described in larger depth in our filings with the Securities and Exchange Fee. We could not really reach the aims or options described in our forward-seeking statements, and buyers need to not place undue reliance on these statements. Ahead-looking statements designed in this press release are manufactured only as of the day hereof, and we disclaim any intent or obligation to update any ahead-hunting statements as a final result of developments occurring soon after the day of this push launch.